EXECUTIVE ENGAGEMENTS
OUTREACH
INTERACTIONS
PARTICIPANTS
VALIDATIONS
COMPETITORS
* Login for a full stack data experience
DATE
APR 2021
TABLES
18
PAGES
73
EDITION
18
PRICE
USD $5450
HIGHLIGHTS
SELECT PLAYERS
Eisai Co. Ltd. (Japan); F. Hoffmann-La Roche Ltd. (Switzerland); GlaxoSmithKline Plc; Novo Nordisk A/S (Denmark); Rhythm Pharmaceuticals (US); VIVUS Inc. (US)
SEGMENTS
» Segment (Anti-Obesity Drugs)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
I. METHODOLOGY |
II. EXECUTIVE SUMMARY |
1. MARKET OVERVIEW |
Influencer Market Insights |
World Market Trajectories |
Impact of Covid-19 and a Looming Global Recession |
Obesity and Overweight Statistics |
Recent Market Activity |
Obesity - A Prelude |
Anti-Obesity Drugs: A Market Characterized by High Unmet Needs |
Currently Available Anti-Obesity Medications |
Select Currently Available Short-term and Long-term Anti-Obesity Medication |
Select Off-Label Drugs for Obesity |
Saxenda Commands the AOM Market, Newer Drugs to Provide Impetus to Market Growth |
Semaglutide: Highest Potential in the AOM Pipeline |
Setbacks of Past Drugs |
Positive Road Ahead for Belviq |
Relaunch of Xenical |
Relaunch of Contrave® |
Reluctance among Patients, Physicians, and Payers Hurts Market Prospects |
New Drug Development - High on the Agenda, Despite the Market Restraints |
Anti-Obesity Drugs in Phase-III Clinical Trials: As of July 2018 |
Anti-Obesity Drugs in Phase-II Clinical Trials: As of July 2018 |
Anti-Obesity Drugs in Phase-I Clinical Trials: As of July 2018 |
Diabetes Drug Companies Attempt to Foray into the Anti-Obesity Drugs Space |
Competitive Landscape |
Novo Nordisk - The Leading Player in the Market |
The United States - The Largest Obesity and Anti-Obesity Market |
Europe - A Market with Vast Potential |
Obesity Creeps Up in Developing Countries |
2. FOCUS ON SELECT PLAYERS |
F. Hoffmann-La Roche Ltd. (Switzerland) |
GlaxoSmithKline Plc. (UK) |
Eisai Co., Ltd. (Japan) |
Novo Nordisk A/S (Denmark) |
Rhythm Pharmaceuticals (USA) |
VIVUS, Inc. (USA) |
3. MARKET TRENDS & DRIVERS |
Alarming Rise in Global Obesity Levels - The Major Growth Factor |
Classification of BMI |
Rising Incidence of Chronic Diseases Associated with Obesity Drive the Market Expansion |
Growing Middle Class Population to Drive the Market Growth |
Childhood Obesity - A Market with Unmet Needs |
Commercial Weight-Loss Companies Foray into the Market |
Online Drug Stores Boost Sales |
Barriers to Development of Effective Drugs |
Regulatory Additions - A Barrier to Entry? |
High Drug Development Costs - A Major Setback |
Weight Loss Alternatives - A Market Dampener |
4. GLOBAL MARKET PERSPECTIVE |
World Current & Future Analysis for Anti-Obesity Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World 7-Year Perspective for Anti-Obesity Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027 |
III. MARKET ANALYSIS |
UNITED STATES |
USA Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
CANADA |
Canada Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
JAPAN |
Japan Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
CHINA |
China Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
EUROPE |
Europe Current & Future Analysis for Anti-Obesity Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
Europe 7-Year Perspective for Anti-Obesity Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027 |
FRANCE |
France Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
GERMANY |
Germany Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
ITALY |
Italy Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
UNITED KINGDOM |
UK Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
REST OF EUROPE |
Rest of Europe Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
ASIA-PACIFIC |
Asia-Pacific Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
REST OF WORLD |
Rest of World Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
IV. COMPETITION |
Total Companies Profiled: 25 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com